Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Aclarion, Inc. (ACON)
Company Research
Source: GlobeNewswire
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case studySpecial Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes over 150 articles annually representing 40+ nations BROOMFIELD, Colo., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a featured article Tech Update, sponsored by Aclarion, in the upcoming Special Pain Issue of the International Journal of Spine Surgery (IJSS). “The Special Pain Issue of IJSS highlights a simple truth: pain is not just a symptom—it is a complex neurobiological, psychological, and existential condition,” said Morgan P. Lorio, MD, FACS, Guest Editor. “As more granular diagnostics and
Show less
Read more
Impact Snapshot
Event Time:
ACON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACON alerts
High impacting Aclarion, Inc. news events
Weekly update
A roundup of the hottest topics
ACON
News
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.GlobeNewswire
- Aclarion (NASDAQ:ACON) had its price target raised by analysts at Ascendiant Capital Markets from $22.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market ExpansionGlobeNewswire
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTHGlobeNewswire
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst [Yahoo! Finance]Yahoo! Finance
ACON
Sec Filings
- 12/1/25 - Form 4
- 11/12/25 - Form 10-Q
- 10/14/25 - Form 8-K
- ACON's page on the SEC website